Alembic Pharmaceuticals Limited (NSE: APLLTD)

India flag India · Delayed Price · Currency is INR
1,041.85
+4.00 (0.39%)
Nov 22, 2024, 3:29 PM IST
40.17%
Market Cap 204.79B
Revenue (ttm) 63.57B
Net Income (ttm) 6.47B
Shares Out 196.56M
EPS (ttm) 32.89
PE Ratio 31.68
Forward PE 27.54
Dividend 11.00 (1.06%)
Ex-Dividend Date Jul 15, 2024
Volume 54,704
Open 1,027.60
Previous Close 1,037.85
Day's Range 1,027.30 - 1,048.35
52-Week Range 710.25 - 1,303.90
Beta 0.69
Analysts n/a
Price Target n/a
Earnings Date Nov 8, 2024

About Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ... [Read more]

Sector Healthcare
Founded 1907
Employees 14,858
Stock Exchange National Stock Exchange of India
Ticker Symbol APLLTD
Full Company Profile

Financial Performance

In 2023, Alembic Pharmaceuticals's revenue was 62.29 billion, an increase of 10.19% compared to the previous year's 56.53 billion. Earnings were 6.16 billion, an increase of 80.07%.

Financial Statements

News

Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets

Alembic Pharmaceuticals Limited (Alembic) recently informed exchanges that the US Food and Drug Administration (USFDA) has granted Final Approval for its Abbreviated New Drug Application (ANDA) Ivabra...

11 days ago - Business Upturn

Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules

Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydro...

12 days ago - Business Upturn

Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY

Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected mod...

16 days ago - Business Upturn

Alembic Pharmaceuticals shares surge today – Know More

Alembic Pharmaceuticals saw a rise in its share price today after announcing that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applicati...

4 weeks ago - Business Upturn

Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release capsules

Alembic Pharmaceuticals Limited has recently informed exchanges that it has obtained final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...

4 weeks ago - Business Upturn

Top losers today: DMart down 8.26%, Saregama drops 5.56%, and Tata Chemicals falls 5.04%

At 12:43 PM IST, the market witnessed some significant declines among leading stocks. Below is a table summarizing the top losers: Stock Name Price (₹) Change (%) DMart (Avenue Supermarts) 4,194.95 -8...

5 weeks ago - Business Upturn

Alembic Pharmaceuticals hits 52-week high as its oncology formulations unit successfully completes USFDA inspection

Alembic Pharmaceuticals shares hit a new 52-week high in morning trade after the company successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 48...

6 weeks ago - Business Upturn

Alembic Pharmaceuticals successfully completes USFDA inspection at its Oncology Formulation Facility

Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 483 observatio...

6 weeks ago - Business Upturn

Alembic announces early participation in PM’s internship scheme

Alembic Pharmaceuticals Limited announces its participation in the Prime Minister's internship scheme aimed at providing internship opportunities for one crore young Indians across top companies. Expl...

7 weeks ago - The Times of India

Alembic Pharmaceuticals receives USFDA approval for Alcaftadine Ophthalmic Solution

Alembic Pharmaceuticals Limited has announced that it received final approval from the U.S. Food and Drug Administration (USFDA) for its over-the-counter (OTC) Alcaftadine Ophthalmic Solution, 0.25%. ...

7 weeks ago - Business Upturn

Alembic Pharmaceuticals shares surge 3% after receiving USFDA final approval for Lamotrigine Extended-Release Tablets

Alembic Pharmaceuticals shares jumped more than 3% in morning trade after the US Food and Drug Administration (USFDA) granted final approval for its Abbreviated New Drug Application (ANDA) for Lamotri...

7 weeks ago - Business Upturn

Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets

Alembic Pharmaceuticals Limited announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lamotrigine Exten...

7 weeks ago - Business Upturn

Alembic Pharmaceuticals receives USFDA final approval for Paliperidone Extended-Release Tablets

Alembic Pharmaceuticals Limited has announced its receipt of final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paliperidone Extended-Rel...

2 months ago - Business Upturn

Alembic Pharmaceuticals stock surges 4% after getting USFDA approval for Albendazole tablets

Alembic Pharmaceuticals shares jumped more than 4% in early trade after the company received USFDA approval for Albendazole tablets. The US Food and Drug Administration (USFDA) granted Alembic Pharmac...

2 months ago - Business Upturn

Alembic Pharmaceuticals share jumps 3% after getting USFDA approval for Albendazole tablets

Alembic Pharmaceuticals saw its share surge today after getting approval from the US Food & Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg. As of 1:40 PM, the company’s shares wer...

2 months ago - Business Upturn

Alembic Pharmaceuticals gets USFDA nod for Albendazole tablets

Alembic Pharmaceuticals Ltd has secured final approval from the US Food & Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg. This approval is for the company’s Abbreviated New Drug A...

2 months ago - Business Upturn

USFDA greenlights Alembic Pharmaceutical’s Betamethasone Valerate Foam

Alembic Pharmaceuticals Limited recently disclosed that the US Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Fo...

3 months ago - Business Upturn